Analyst Price Targets — OLMA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 13, 2026 10:41 am | — | Guggenheim | $35.00 | $13.97 | TheFly | Olema Oncology price target lowered to $35 from $38 at Guggenheim |
| March 9, 2026 3:59 pm | Emily Bodnar | H.C. Wainwright | $38.00 | $16.45 | StreetInsider | Olema Pharmaceuticals (OLMA) PT Lowered to $38 at H.C. Wainwright |
| February 10, 2026 9:11 pm | — | Stifel Nicolaus | $48.00 | $23.37 | TheFly | Olema Oncology initiated with a Buy at Stifel |
| January 7, 2026 10:18 am | — | Piper Sandler | $40.00 | $25.04 | TheFly | Olema Oncology initiated with an Overweight at Piper Sandler |
| January 7, 2026 5:49 am | Michael Yee | UBS | $45.00 | $25.04 | StreetInsider | UBS Starts Olema Pharmaceuticals (OLMA) at Buy |
| December 11, 2025 1:56 pm | — | Oppenheimer | $48.00 | $31.66 | TheFly | Olema Oncology price target raised to $48 from $45 at Oppenheimer |
| December 11, 2025 11:52 am | — | Goldman Sachs | $38.00 | $30.68 | TheFly | Olema Oncology price target raised to $38 from $26 at Goldman Sachs |
| December 11, 2025 11:41 am | Emily Bodnar | H.C. Wainwright | $45.00 | $32.22 | StreetInsider | Olema Pharmaceuticals (OLMA) PT Raised to $45 at H.C. Wainwright |
| December 10, 2025 7:20 pm | Michael Yee | Jefferies | $43.00 | $30.66 | TheFly | Olema Oncology price target raised to $43 from $30 at Jefferies |
| November 21, 2025 12:15 pm | — | Goldman Sachs | $26.00 | $22.01 | TheFly | Olema Oncology price target raised to $26 from $18 at Goldman Sachs |
Latest News for OLMA
Olema Pharmaceuticals, Inc. (OLMA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
SAN FRANCISCO, June 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to six new employees to purchase an aggregate of 176,150 shares of the Company's…
Study to evaluate OP-3136, Olema's novel KAT6 inhibitor, in combination with darolutamide in approximately 36 patients; expected to initiate in H2 2026 First clinical collaboration for OP-3136; results to inform combination strategy in metastatic prostate cancer setting SAN FRANCISCO, May 26, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage…
OP-3136 monotherapy was well-tolerated with no dose-limiting toxicities observed and no discontinuations due to treatment-related adverse events OP-3136 shows evidence of anti-tumor activity across multiple solid tumor types Data support the ongoing Phase 1 evaluation of OP-3136 as a monotherapy and in combination with fulvestrant and palazestrant SAN FRANCISCO, May 21, 2026 (GLOBE NEWSWIRE) -- Olema…
SAN FRANCISCO, May 19, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences: TD Cowen 7 th Annual Oncology Innovation…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for OLMA.
U.S. House Trading
No House trades found for OLMA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.